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Background: Strokes are a common cause of adult disability and mortality worldwide. Transient ischaemic attacks
(TIA) are associated with a high risk of subsequent stroke, and rapid intervention has the potential to reduce stroke
burden. This study will assess a novel electronic decision support (EDS) tool to allow general practitioners (GPs) to
implement evidence-based care rapidly without full reliance on specialists.
Methods/design: This is a cluster randomized controlled trial comparing TIA/stroke management of GPs with
access to the EDS tool versus usual care. The intervention period is 12 months with a 3-month follow-up period for
individual patients. Primary outcomes consist of stroke within 90 days of presenting event and adherence to the
New Zealand national TIA guideline.
Discussion: A positive study will provide strong evidence for widespread implementation of this tool in practice
and has the potential to improve key outcomes for patients and reduce the burden of stroke.
Trial registration: Australia New Zealand Clinical Trials Registry ACTRN12611000792921
Keywords: Stroke, Ischaemic Attack, Transient (TIA), Electronic Decision Support (EDS), Decision Support
Techniques, Decision Making, Computer-Assisted, Delivery of Healthcare, IntegratedBackground
Stroke is the second most common cause of death
worldwide and the most common cause of long term
adult disability in developed countries [1,2] Stroke costs
New Zealand over $450 million every year [3]. If current
trends in stroke incidence and mortality continue [4-6],
the number of stroke survivors in New Zealand will
reach 50,000 by 2015 [7], with overall annual costs of
> $700 million. Reducing the burden of stroke is a key
goal for health service planning [8].
Transient ischaemic attacks (TIAs) identify people at
high risk of stroke. TIA is defined as transient loss of focal
cerebral or ocular function lasting <24 hours, attribut-
able to ischaemic vascular disease. TIAs precede stroke in
approximately 25% of stroke victims. The 24-hour cut-
off point is arbitrary and minor strokes, defined as symp-
tom duration of >24 hours but with subsequent complete* Correspondence: anna.ranta@otago.ac.nz
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reproduction in any medium, provided the oror near complete recovery, carry the same high risk of
subsequent stroke as TIAs. Both indicate circulatory
compromise of brain tissue that is at risk of infarction,
but which is yet entirely or nearly entirely salvageable.
Transient cerebral ischemia is typically caused by un-
stable plaques affecting the larger vessels that supply
large amounts of brain tissue. As a result, the majority of
strokes that follow TIA or minor stroke are severely dis-
abling or fatal, and these are most likely to occur within
48 hours and up to seven days following TIA while the
plaque remains ‘fresh’ [9]. This highlights the importance
of urgent intervention to maximize stroke prevention in
high-risk patients. A key intervention that reduces sub-
sequent stroke is rapid initiation of best medical therapy
via urgent (<24 hour) specialist review [10,11]. Care fol-
lowing this model has been associated with an 80% reduc-
tion in 90-day stroke risk from 10.3% to 2.1% (adjusted
hazard ratio 0.20, 95% CI 0.08 to 0.49; p = 0.0001) [10].
In New Zealand, providing 24-hour, seven days a
week, rapid access specialist TIA clinics is challenging,
especially in the smaller district health boards (DHBs),
where patient numbers cannot support a sufficient numbertd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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clock specialist service. A UK study has shown that most
patients experiencing TIA or minor stroke first seek
healthcare from their general practitioner (GP) [12], even
when the event occurs outside normal working hours.
Thus, in a setting of limited specialist access it seems lo-
gical to look for ways that urgent intervention could be
offered at the GP level in order to avoid unnecessary and
potentially life-threatening treatment delays. However, the
scope of clinical conditions managed in general practice is
very broad, and individual GPs will have patients present-
ing to them with TIA/stroke relatively infrequently. Our
analysis of general practice records suggests that, on aver-
age, a GP will be consulted four to five times per year
by a patient presenting with a presumed TIA/minor
stroke. However, GP diagnostic accuracy of TIA/minor
stroke is only 50% to 80% [13], so the actual rate of recog-
nized TIA/minor stroke patients encountered by GPs may
be as few as two to three patients per year.
Electronic clinical decision support systems (EDS) may
be especially valuable for assisting clinical decision-
making in such circumstances, where a condition is both
challenging to diagnose correctly and encountered by
generally clinicians relatively infrequently. New Zealand’s
MidCentral Stroke Service, in collaboration with the Best
Practice Advocacy Centre Inc. (BPAC), has developed a
novel TIA/stroke EDS tool. The tool may mitigate the
problem of limited or delayed specialist assessment in a
setting in which many GPs lack the experience necessary
to manage TIA/stroke independently. It aids GPs to
accurately diagnose TIAs, promoting treatment initiation
at first point of contact rather than awaiting specialist
review, and prompts GPs to manage TIA and stroke
patients comprehensively and in accordance with New
Zealand guidelines [13].
One of the benefits of the EDS tool is that it is inher-
ently educational, providing GPs with immediate feed-
back on diagnosis and guideline based advice, which can
be applied to the management of future patients and
improve diagnostic and management skills over time.
Throughout New Zealand, similar BPAC decision sup-
port modules are used by 76% of general practices and
85% of GPs. The TIA/stroke module differs from other
existing modules because it focuses on the management
of an acute medical problem rather than chronic care or
disease prevention. However, in its operation it mimics
other existing tools. The TIA/stroke tool is a new module
that has so far been used only in the MidCentral DHB.
National implementation of the TIA/stroke decision sup-
port module has the potential to significantly reduce
the burden of stroke throughout New Zealand. However,
its use may also involve two main possible threats to
patient safety: patients may be erroneously diagnosed as
not having a TIA and miss out on early treatment and/orspecialist referral; and patients may be erroneously diag-
nosed with a TIA and placed needlessly on potentially
harmful medications such as aspirin.
There has been no research investigating impacts of any
BPAC EDS modules on clinical behavior and patient out-
comes in New Zealand. International evidence on whether
point-of-care decision support improves patient care has
been equivocal [14,15]. Decision support tools are becom-
ing ubiquitous throughout New Zealand primary care and
their utility should be carefully evaluated. In particular, do
they assist clinicians to make evidence-based clinical deci-
sions? In a literature review, we identified 175 published
reports of research into EDS use in primary care settings,
but no tool that addresses the complex clinical care needed
for initial presentation of TIA/stroke. Systematic reviews of
the decision support literature conclude that there is a
shortage of well-designed randomized controlled trials of
EDS that provide assessments of its effectiveness in chan-
ging patient outcomes, as well as in changing clinician be-
havior [16-21].
To date, we have conducted four studies to assess the
TIA/stroke decision support tool. A pre-launch commu-
nity-based pilot indicated a high degree of GP satisfaction,
excellent guideline adherence when the tool’s management
advice was followed closely, and no adverse patient out-
comes [22]. A second study comparing stroke experts, GPs,
and decision support management in seven sample cases
found that management was guideline adherent 33%
among GPs without EDS, 92% among specialists, and 100%
when the decision support tool was used [23]. Data from a
before-and-after study in the MidCentral DHB showed that
best medical therapy was in place within 24 hours in 31%
of patients before introduction of the EDS system and 52%
after its introduction [24]. Finally, a recent unpublished
audit of all patients managed using the EDS for the
18 months following its launch has not found any signifi-
cant adverse events associated with its use. Although re-
assuring and promising these small non-experimental
studies support the need for a well-designed randomized
controlled trial to assess this novel treatment approach.
The aim of the FASTEST trial is to formally test the effi-
cacy and safety of New Zealand’s TIA/stroke decision sup-
port tool in comparison with usual care. This study has
received funding from the Health Research Council of New
Zealand (grant 11/268), ethics approval from the Ministry
of Health Multi-region Ethics Committee (URA/11/08/
048) and has been under way since November 2011.
Methods/Design
Design
Cluster randomized controlled trial of general practices
with and without TIA/stroke EDS, comparing TIA and
stroke management strategies, outcomes, and cost in
each arm.
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The decision support tool is an internet-based module
provided and maintained by BPAC. GPs access this tool
by clicking a menu button situated on the navigation bar
of their practice management software that links them to
the BPAC module site. From there they select the TIA/
stroke tool from a menu. Once selected, a single page of
tick boxes opens up for GPs to complete covering items
such as relevant aspects of presenting illness history and*PMS = Practice Management System i.e. GP electro
Figure 1 TIA/stroke EDS Data Entry Form with sample case.a brief focused physical examination. Fields for relevant
past medical history (e.g., diabetes and smoking history)
are automatically populated by extracting data directly
from the practice management system (Figure 1).
Completing the page of background and clinical pres-
entation data takes approximately two to five minutes
depending on the GP’s familiarity with the tool. Based
on this information, the software confirms or rejects
TIA/stroke as the likely diagnosis. If TIA or stroke is‘Communication/speech 
problems’ ticked resulting 
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on the validated ABCD2 risk score [25] supplemented
by several other variables taken from the New Zealand
TIA guidelines [13] (Figure 2). If patients are triaged into
the ‘low risk’ category, GPs are offered the option of
either referring them to a TIA clinic for specialist review
within seven days or of managing the patients them-
selves in the community. If community management is
selected, a step-by-step outline is provided with links to
pre-populated relevant prescriptions, radiology referral
forms, and a variety of patient information leaflets
(Figure 3). If patients are triaged into the ‘high risk’
category, GPs are advised to refer them to hospital
immediately for specialist assessment and diagnostic
work-up to be achieved within 24 hours, and GPs are
not offered the community management option. How-
ever, if a GP feels that urgent hospital referral is not
appropriate in any given situation (e.g., the patient
refuses to attend the Emergency Department), then
GPs have the option to override this recommendation
and refer patients to an outpatient specialist TIA
clinic instead, as long as a reason for overriding the
recommendation is specified. Hospital referral forms
are automatically generated and contain all informa-
tion needed for specialists to prioritize patients ap-
propriately. In the case of a hyper-acute stroke with
unresolved symptoms that started within the preced-
ing 4.5 hours (i.e., within the thrombolysis window)
the tool is immediately aborted and the GP is advised
to call 111 for emergent hospital transfer to a centre
where stroke thrombolysis is available.
To preserve patient confidentiality, all patient data for
the study generated by the decision support tool areFigure 2 Sample Outcome Page for a low-risk patient with typical TIAtransmitted in an encrypted format to BPAC and from
there to the research team.
Outcome measures
The two primary outcome measure are recurrent stroke
within 90 days of initial presentation with TIA or stroke
and management in accordance with New Zealand TIA
guidelines with regard to: treatment with anti-platelet
therapy being achieved within 24 hours of presentation;
treatment with statin, anti-hypertensive, and/or warfarin
(if applicable and not contraindicated) being achieved as
soon as clinically indicated and deemed safe; and receipt
of appropriate diagnostic investigations within 24 hours
or seven days based on risk stratification.
Secondary outcomes include: adverse events (including,
but not limited to, medication side effects, diagnostic
delays, and misdiagnoses); occurrence of recurrent TIA,
myocardial infarction, major bleeding, and/or death
within 90 days; implementation of a comprehensive adju-
vant treatment plan (smoking cessation counseling, exer-
cise/diet advice, communication of driving restrictions,
and education on thrombolysis); overall treatment cost
(including both direct cost relating to treatment of index
event and cost of any events related to presenting com-
plaint during the follow-up period); and GP and TIA
clinic specialist satisfaction.
Sample size calculation
The primary outcome is the proportion of participants who
have recurrent stroke within 90 days of the presenting TIA/
stroke. Based on previous work [9,11,24], we estimate that
10% of patients in the control group will have a stroke or
TIA compared to 2% of patients in the intervention group.Clicking or hovering over blue 
links or an opens a pop-up 
window with added 
information for the user and/or 
generates referrals, 
prescription or patient leaflets
symptoms.
Figure 3 Sample ‘comprehensive TIA/stroke work-up in the community’ instructions for low-risk TIA patient with typical anterior
circulation symptoms.
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of 274, one-half in each of two treatment arms, is
needed to detect this size difference with 80% power and
type I error rate of 5% [26]. We planned to recruit
40 practices, representing clusters, and used an intra-
class correlation coefficient of 0.01 similar to the median
intra-class correlation in the paper of Adams [27]. Based
on an average of seven participants per practice, the
adjusted sample size needed is 292.
This is achievable in 12 months assuming an average
of 2.5 GP full-time equivalents per practice and an aver-
age of two to three TIA/minor stroke patients per GP
per year. The sample size calculation also takes into
account an expected 50% to 80% [13] GP diagnostic
accuracy. We anticipate that an average of four to five
patients will be registered in the study per GP over
12 months, but with an average of only two to three
patients having actually suffered a true TIA or minor
stroke.
A pre-specified second primary outcome is the pro-
portion of patients who receive management according
to New Zealand TIA guidelines. This outcome is likely
to be achieved for around 33% of usual care participants
compared to an anticipated 92% in the intervention group
[23]. Unadjusted for the cluster design, this requires a totalsample size of 20 patients. The intra-class correlation co-
efficient for this outcome will be much higher. Based on
a value of 0.4, the study is still likely to have sufficient
power to detect this difference.
Practice engagement
Three districts (Hawke’s Bay and Whanganui in the
North Island and the Southern region in the South Island)
were chosen to participate in this study. All practices in
these areas have access to a hospital based specialist run
TIA clinic for consultations during regular hours. All of
their practices will have access to 24 hour/7 day-a-week
acute medical care in the hospital inpatient setting.
GPs are eligible to participate in the study if their
practices use an electronic practice management system
and they agree to be randomized into either the inter-
vention group (using the TIA/stroke decision support
tool) or the control group (who agrees not to use the
TIA/stroke tool) for the 12 months of the intervention
phase. All practices in these districts were invited by
letter to participate, followed by individual phone calls
to promote timely recruitment. GPs were then invited to
attend an educational session where the Principle Investi-
gator (PI) reviewed management principles of TIA and
stroke and the study’s processes in detail. Representatives
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sions, confirmed their willingness to participate, signed
consent forms, and were randomized on the spot. Posters
were provided for practices to have in their waiting
rooms, advising patients of the practice’s involvement in
the study. Out of the 136 GP practices in these three
regions, 44 practices were successfully recruited by the
planned intervention start date of 1 March 2012.
A randomization schedule for participating practices
was drawn up by the statistical advisor to the project
(MW).
After use of the EDS tool, there are some instances
when GPs require rapid access to carotid ultrasound or
head computed tomography (CT). This is not currently
available in the public health system to most GPs
enrolled in the trial and related costs for private
provision of carotid ultrasound and head CT will be
funded through the study to ensure that all patients have
similar access to diagnostic tests in the different regions
of the study. GP access to these tests endorsed by EDS
triage/recommendation is an important aspect of the
intervention and has to be assured.
Study data
GPs in both the intervention and control groups have
been provided with a menu button situated on the navi-
gation bar of their practice management software () indi-
cating the link to register patients for the study. GPs will
click the button when they encounter a patient they
believe to be suffering from a TIA or stroke. In the con-
trol group, the button click will prompt patient clinical
details to be registered and stored centrally by BPAC and
the GP will be advised to continue with routine care.
In the intervention group, clicking the button will open
up the TIA/stroke EDS module and the GP will then use
the software. For each patient in the intervention group,
information about diagnosis, triage advice, and manage-
ment plan given to the GP by the EDS tool will be
recorded and stored centrally at BPAC, in addition to
patient clinical details.
Throughout the trial and at the end of the 12-month
intervention period, records of all patients entered into
the BPAC database via the procedure described above
will be reviewed for outcome measures three or more
months after being registered. GP records will be scru-
tinized and all data collected will be verified and sup-
plemented by hospital and coroners’ records when
applicable. Data collection will be accomplished by a
study clinician via use of an electronic Microsoft Access
tick box form to facilitate efficient data analysis.
Specific data collected about patients include: final
diagnosis including anatomic localization (confirmed by
specialist)—TIA, ischaemic stroke, hemorrhagic stroke, or
other and anterior versus posterior localization; ABCD2score if available; initial GP triage destination (commu-
nity, hospital, or TIA clinic); past medical history of atrial
fibrillation, current warfarin use, more than one TIA/
stroke event over past seven days (all high risk indicators);
medical treatment with antiplatelet(s), statin, and/or
antihypertensive accomplished in <24 hours, 24 hours
to 7 days, or >7 days; documentation of counseling/
education (smoking, diet/exercise, driving, thrombolysis)
and by whom it was provided (GP/practice nurse,
hospital physician, hospital nurse); investigations and
time frame (< 24 hours, 24 hours to 7 days, > 7 days) for
ECG, CT head, MRI, echocardiogram, Holter monitor,
and carotid ultrasound if obtained; hospital specialist re-
view ‘yes/no’ in < 24 hours, 24 hours, to 7 days, > 7 hours;
hospitalizations related to index event ‘yes/no,’ if yes
number of days in hospital and discharge location; and
TIA, stroke, MI, major bleeding or death within three
months of index event, any significant adverse events
attributable to medications prescribed after index
event, diagnostic delays, and/or misdiagnosis (‘signifi-
cant event’ is defined as an event that prompted a GP
visit/phone call, hospitalization or death). All identifi-
able data will be expunged from the final dataset to be
analyzed for the study, leaving patients identified only
by a unique study code.
In addition, at the end of the study, GPs will be sur-
veyed regarding satisfaction with the tool as regards
usability, efficiency, and any patient concerns of which
they have been made aware. Specialists providing care
through a TIA clinic will be surveyed regarding satis-
faction with referral quality and any concerns or obser-
vations they have made comparing management with
versus without TIA/stroke EDS.
Analysis
This is a single-blinded study with the statistician ana-
lyzing the results blinded to the study group of partici-
pants. The statistician analyzing the data will be based in
a different geographical site from the team managing the
study and collecting the data. The analyst will be pro-
vided with a data file from which all patient, practice,
and study group identifying data has been expunged.
These variables will be replaced in the analyst’s file with
non-identifiable numeric codes. Before being provided
with the data file for analysis, the principal investigator
and one other investigator will check the data to ensure
that all potentially identifying information has been
removed.
The analysis will use a generalized linear mixed model
to take account of both the dichotomous outcome vari-
ables and the cluster design. These models are more
complex than generalized linear models or mixed linear
models. The outcomes for individual patients will be the
response variables, but we will take account of the
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treatment interaction effects as random effects. We may
have to explore if the practice-treatment interaction
effect has a non-zero value and fit a simpler model.
PROC GLIMMIX in SAS will be used to fit the models
[28-30].
Analysis of the outcomes will include all patients
registered by the GPs, including those who eventually
turn out to have a diagnosis other than TIA/stroke
(i.e., ‘intention-to-treat’ analysis). However, a pre-specified
secondary analysis is of the main outcomes for only
patients who were confirmed to have suffered an actual
TIA or minor stroke by specialist assessment.
Cost comparisons
This study is focused on short-term costs and conse-
quences of the proposed intervention, occurring within
three months of the initial TIA or stroke.
All costs will be measured as at a specified date. For
example, as 'dollars in year 2010 prices,’ or 'year ending
in June 2011.’ Costs measured in dollars of another date
will be adjusted using appropriate price or cost indices
to the chosen 'base date.’ The chosen date will be the
latest period, at the time of carrying out the analyses, for
which the necessary price or cost indices are available.
All costs will be measured excluding Goods and Services
Tax (GST). This means that any raw data will be clearly
identified as either including or excluding GST, and, in
the former case, adjusted to remove GST.
The costs associated with using the intervention
(purchase of the computer module from BPAC plus any
installation, training, and support costs) will be included
in the cost analysis. These costs apply of course to the
'intervention arm' only. Other costs will be collected in
tandem with the collection of clinical information, for
both 'intervention' and 'control' arms of the trial. That is,
costs will be collected for every individual reporting to a
practice in the trial with a TIA/stroke. The advantage of
collecting data at individual level is that standard devia-
tions and confidence intervals for the cost estimates can
then be readily calculated [31]. Also, simulation techni-
ques can subsequently be applied, if desired, to assess the
robustness of the conclusions reached from the research.
Costs will be collected for the following: GP visit;
ambulance/transport cost; specialist consultation; hospital
stay; investigations (ECG, CT, carotid ultrasound, MRI,
echocardiogram, Holter monitor, laboratory tests); medi-
cations (hospital and ex-hospital).
In general the approach to costing will follow that laid
down in Pharmac’s latest (2012 edition) Prescription for
Pharmacoeconomic Analysis [32]. (Pharmac is the New
Zealand agency that decides which pharmaceuticals
qualify for government subsidy, and the amount of
subsidy). Where applicable 'standard costs' given in theCost Resource Manual [33] provided by Pharmac, such
as the average cost per GP consultation, will be used.
For consultations and medications any subsidy to patients
will be added back to give total cost pre-subsidy. For
hospital admissions (day-patient or in-patient), the ap-
propriate diagnosis-related grouping cost-weight will be
used and length of stay data will also be collected for
collateral information.
Discussion
The study is challenging, and there are a number of
important issues we have attempted to address in the
study design.
Study results are intended to be widely applicable
nationally and internationally. Involving practices from
both North and South Island sites ensures that data
will be applicable to a wide range of geographical sites
throughout New Zealand. All three study regions are
DHBs with relatively small, geographically dispersed popu-
lations. On the one hand, this makes them representative
of areas that may benefit the most from this type of
intervention; yet, our focus on smaller centers may limit
application of study data to larger urban centers. To off-
set this, we have included one DHB centered around a
tertiary university medical centre (University of Otago,
Dunedin School of Medicine). The three largest popula-
tion centers in New Zealand (Auckland, Christchurch,
and Wellington) were excluded from recruitment be-
cause they either have other pathways in place that
would take significant time and effort to align with the
decision support tool or are in the process of restructur-
ing their services that precluded trial involvement.
Secondly, it can be argued that a cluster randomized
design may not be appropriate for this study. However,
in the study design we felt that randomization should be
at the practice level (cluster design) in order to minimize
any potential learning effect created by software use. We
decided we should not randomize individual patients be-
cause the EDS tool educates GPs on guideline based care
and this would affect the care of later patients rando-
mized to the placebo arm and considerably dilute any
intervention effect should one exist. Even randomizing
GPs to different groups within a practice may have lead
to potential confounding because colleagues may discuss
cases and their management with one another. GPs
within a practice may also cover for one another, which
risks inconsistency in EDS use should serial visits occur
by a single patient. On the other hand, cluster designs
carry the risk of confounding because similar GPs may
naturally group themselves in collegial practices. This is
addressed in the study design by an increase in sample
size to offset the cluster effect.
Another issue is that activation of a ‘registration’
button automatically draws GPs’ attention to the fact
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patient management. Furthermore, practices volunteer-
ing for the study may be generally more motivated than
non-volunteers, which may introduce some degree of
selection bias. Both these effects may dilute measured
benefit of the intervention because both sources of bias
may improve the level of care in the placebo group com-
pared with average GP care encountered in other prac-
tices in the country. Thus, while this may make it more
difficult for the study to define a significant difference
between intervention and placebo, we feel reassured
that a false positive trial result is unlikely.
With regard to economic assessments because of the
short-term focus of the study, the following items were
excluded: lost economic contribution (or lost product-
ivity), i.e., the income from employment lost because of
either premature mortality or inability to work because
of illness (Pharmac [32] recommends the exclusion of
these ‘indirect patient costs’); and the cost of post-hospital
institutionalization, nursing care, and social services.
These, if included, could be expected, if the intervention is
effective, to favor the intervention. In order to get some
indication of this effect, discharge location (home, hospital
level, or residential home-level care) will be recorded
during data collection. Furthermore, lost Quality-adjusted
Life-Years (QALYs) will also not be included. Strictly
speaking, these are a 'health outcome' rather than an eco-
nomic cost and will be indirectly captured in the number
of strokes occurring in each study arm.
Lastly, the primary outcome of 90-day stroke rate may
be difficult to achieve. The study was powered to achieve
this outcome, but the only available data on post-TIA
stroke rates is now several years old, and the recent
more widespread use of secondary preventive medica-
tions due to significant efforts toward cardiovascular risk
reduction may have had a significant impact on current
stroke rates. To account for this potential difficulty, we
have selected a second primary outcome in the form of
overall guideline adherence.
Overall, we anticipate that information from this study
will allow DHBs to decide if wider implementation
should go ahead and GPs to decide whether to use the
tool. Should the BPAC TIA/stroke EDS tool be found to
improve key outcomes for patients then its widespread
use has the potential to reduce the burden of stroke in
New Zealand.
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